Benralizumab injection improved respiratory symptoms within 28 days and reduced treatment failures by fourfold after 90 days compared to standard steroid therapy.

RT’s Three Key Takeaways:

Improved Respiratory Symptoms – Benralizumab significantly reduced symptoms such as cough, wheeze, and breathlessness within 28 days of treatment.
Fewer Treatment Failures – After 90 days, patients receiving benralizumab experienced four times fewer treatment failures compared to those on standard steroid therapy.
Targeted Therapy Advantage – The study demonstrated that administering benralizumab during exacerbations is more effective than traditional steroids, potentially offering a more tailored approach for asthma and COPD management.

An injection given during some asthma and COPD attacks is more effective than the current treatment of steroid tablets, reducing the need for further treatment by 30%.

The findings, published in The Lancet Respiratory Medicine, could be “game-changing” for millions of people with asthma and COPD around the world, scientists say.

The type of symptom flare-up the injection treats is called eosinophilic exacerbations and involve symptoms such as wheezing, coughing, and chest tightness due to inflammation resulting from high amounts of eosinophils (a type of white blood cell). Eosinophilic exacerbations make up to 30% of COPD flare-ups and almost 50% of asthma attacks. They can become more frequent as the disease progresses, leading to irreversible lung damage in some cases.

[Benralizumab Reduces Need for Inhaled Steroids for Severe Asthma]

Treatment at the point of an exacerbation for this type of asthma has barely changed for over 50 years, with steroid drugs being the mainstay of medication. Steroids such as prednisolone can reduce inflammation in the lungs but have severe side effects such as diabetes and osteoporosis. Furthermore, many patients “fail” treatment and need repeated courses of steroids, re-hospitalisation, or die within 90 days.

Trial Highlights Benralizumab’s Effectiveness Over Steroids in Reducing Lung Flare-Ups

Results from the phase two clinical trial ABRA study, led by scientists from King’s College London and sponsored by the University of Oxford, show a drug already available can be re-purposed in emergency settings to reduce the need for further treatment and hospitalizations. The multi-centre trial was conducted at Oxford University Hospitals NHS Foundation Trust and Guy’s and St Thomas’ NHS Foundation Trust.

Benralizamab is a monoclonal antibody that targets specific white blood cells, called eosinophils, to reduce lung inflammation. It is currently used for the treatment of severe asthma. The ABRA trial has found a single dose can be more effective when injected at the point of exacerbation compared to steroid tablets.

The study investigators randomized people at high risk of an asthma or COPD attack into three groups: one receiving benralizumab injection and dummy tablets, one receiving standard of care (prednisolone 30mg daily for five days) and dummy injection, and the third group receiving both benralizumab injection and standard of care. As a double-blind, double-dummy, active-comparator placebo-controlled trial, neither the people in the study nor the study investigators knew which study arm or treatment they were given.

After 28 days, respiratory symptoms of cough, wheeze, breathlessness, and sputum were found to be better with benralizumab. After 90 days, there were four times fewer people in the benralizumab group that failed treatment compared to standard of care with prednisolone.

Treatment with the benralizumab injection took longer to fail, meaning fewer episodes to see a doctor or go to the hospital. There was also an improvement in the quality of life for people with asthma and COPD.

Targeted Benralizumab Therapy Offers Promising Shift in Asthma and COPD Care

Lead investigator of the trial professor Mona Bafadhel from King’s College London says in a release, “This could be a game-changer for people with asthma and COPD. Treatment for asthma and COPD exacerbations have not changed in 50 years despite causing 3.8 million deaths worldwide a year combined.

“Benralizumab is a safe and effective drug already used to manage severe asthma. We’ve used the drug in a different way—at the point of an exacerbation—to show that it’s more effective than steroid tablets which is the only treatment currently available. The big advance in the ABRA study is the finding that targeted therapy works in asthma and COPD attacks. Instead of giving everyone the same treatment, we found targeting the highest risk patients with very targeted treatment, with the right level of inflammation was much better than guessing what treatment they needed.”

The benralizumab injection was administered by healthcare professionals in the study but can be potentially administered safely at home, in the GP practice, or in the emergency department. Benralizumab was safe in the study and similar in safety to many past studies.

Bafadhel says in a release, “We hope these pivotal studies will change how asthma and COPD exacerbations are treated for the future, ultimately improving the health for over a billion people living with asthma and COPD across the world.”

This research was conducted with support from AstraZeneca UK Limited.